7Baggers

BridgeBio Pharma, Inc
(NASDAQ:BBIO) 

BBIO stock logo

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs inc...

Founded: 2015
IPO Price: $17 (Jun 27, 2019)
Full Time Employees: 369
CEO: Neil Kumar  
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 
                                
      revenues:
    		                            
      net product revenue
    		180,596,000 146,017,000 108,111,000 71,501,000 36,739,000                        
      license and services revenue
    		4,419,000 2,881,000 8,311,000 37,440,000 79,894,000        1,826,000 1,775,000 338,000 73,746,000             
      royalty revenue
    		9,500,000 5,280,000 4,278,000 1,624,000                         
      total revenues
    		194,515,000 154,178,000 120,700,000 110,565,000 116,633,000                        
      yoy
    		66.78%                            
      qoq
    		26.16% 27.74% 9.17% -5.20%                         
      operating costs and expenses:
    		                            
      cost of revenues:
    		                            
      cost of goods sold
    		7,732,000 6,777,000 4,028,000 2,848,000 2,034,000                        
      cost of license, services, and royalty revenue
    		2,207,000                            
      total cost of revenues
    		9,939,000 8,107,000 6,563,000 3,653,000 2,639,000                        
      research and development
    		126,636,000 116,417,000 112,874,000 111,231,000 111,431,000 130,350,000 120,444,000 114,695,000 140,972,000 130,226,000 125,136,000 107,488,000 92,861,000 90,902,000 92,511,000 108,400,000 107,649,000 122,200,000 104,305,000 101,960,000 122,559,000 90,174,000 92,050,000 86,598,000 68,225,000 57,485,000 55,278,000 52,331,000 
      selling, general and administrative
    		163,896,000 158,085,000 137,621,000 129,154,000 106,365,000 94,782,000 68,819,000 59,523,000 65,807,000 47,583,000 35,777,000 36,122,000 31,108,000 31,862,000 31,188,000 36,426,000 43,713,000 54,749,000 46,084,000 45,970,000         
      restructuring, impairment, and related charges
    		                            
      total operating costs and expenses
    		300,471,000 293,740,000 265,899,000 244,843,000 221,005,000 231,909,000 194,482,000 177,707,000 210,777,000 179,161,000 161,783,000 147,740,000 127,989,000 131,102,000 129,454,000 153,922,000 175,372,000 178,500,000 151,843,000 148,039,000         
      income from operations
    		-105,956,000 -139,562,000 -145,199,000 -134,278,000 -104,372,000 -226,027,000 -191,750,000 -175,539,000 343,000 -177,416,000 -157,692,000 -146,099,000 -126,163,000 -129,232,000 -129,116,000 -80,176,000 -173,678,000 -165,614,000 -149,499,000 -94,015,000 -167,504,000 -127,489,000 -119,939,000 -124,567,000 -102,487,000 -78,638,000 -54,532,000 -69,249,000 
      yoy
    		1.52% -38.25% -24.28% -23.51% -30529.15% 27.40% 21.60% 20.15% -100.27% 37.28% 22.13% 82.22% -27.36% -21.97% -13.63% -14.72% 3.69% 29.90% 24.65% -24.53% 63.44% 62.12% 119.94% 79.88%     
      qoq
    		-24.08% -3.88% 8.13% 28.65% -53.82% 17.88% 9.23% -51277.55% -100.19% 12.51% 7.94% 15.80% -2.37% 0.09% 61.04% -53.84% 4.87% 10.78% 59.02% -43.87% 31.39% 6.29% -3.72% 21.54% 30.33% 44.21% -21.25%  
      operating margin %
    		-54.47% -90.52% -120.30% -121.45% -89.49% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      other income, net:
    		                            
      interest income
    		6,246,000 4,332,000 6,239,000 3,898,000 5,385,000 4,683,000 3,296,000 5,195,000 4,075,000 5,578,000 3,793,000 4,514,000 4,153,000 4,092,000 2,417,000 766,000 267,000 182,000 234,000 323,000 394,000 448,000 692,000 934,000 1,941,000 2,410,000 2,736,000 1,662,000 
      interest expense
    		-12,942,000 -11,636,000 -11,739,000 -37,637,000 -42,141,000 -29,821,000 -23,061,000 -22,937,000 -23,471,000 -20,268,000 -20,306,000 -20,594,000 -20,121,000 -19,990,000 -19,825,000 -20,279,000 -20,344,000 -15,134,000 -11,067,000 -10,839,000 -9,738,000 -10,962,000 -10,929,000 -10,754,000 -4,010,000 -3,040,000 -2,113,000 -1,941,000 
      noncash interest expense on deferred royalty obligations
    		-39,873,000 -38,678,000 -36,410,000                          
      loss on extinguishment of debt
    		    -21,155,000    -26,590,000                    
      net loss from equity method investments
    		-18,283,000 -21,029,000 -15,834,000 -20,189,000 -15,556,000 -16,695,000 -6,563,000                      
      other income
    		4,253,000 11,818,000 16,461,000 6,548,000 8,231,000 1,624,000 1,797,000 -632,000 9,483,000 21,778,000 -5,283,000 1,476,000  4,560,000 6,331,000 -10,816,000 -7,575,000 28,284,000 -684,000 2,457,000 5,766,000 2,978,000 9,000 -1,827,000 474,000 -10,000 -26,000 -7,000 
      total other expense
    		-60,599,000        -36,503,000                    
      net income
    		-166,555,000 -194,635,000 -184,937,000 -183,758,000 -169,608,000 -267,389,000 -164,254,000 -75,544,000 -36,160,000 -170,328,000 -179,488,000 -160,703,000 -142,732,000 -140,570,000 -140,193,000 -2,559,000 -201,330,000 -152,282,000 -161,016,000 -102,074,000 -171,082,000 -135,025,000 -130,167,000 -136,214,000 -104,082,000 -84,151,000 -60,664,000  
      yoy
    		-1.80% -27.21% 12.59% 143.25% 369.05% 56.98% -8.49% -52.99% -74.67% 21.17% 28.03% 6179.91% -29.11% -7.69% -12.93% -97.49% 17.68% 12.78% 23.70% -25.06% 64.37% 60.46% 114.57%      
      qoq
    		-14.43% 5.24% 0.64% 8.34% -36.57% 62.79% 117.43% 108.92% -78.77% -5.10% 11.69% 12.59% 1.54% 0.27% 5378.43% -98.73% 32.21% -5.42% 57.74% -40.34% 26.70% 3.73% -4.44% 30.87% 23.68% 38.72%   
      net income margin %
    		-85.63% -126.24% -153.22% -166.20% -145.42% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% 
      net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests
    		2,512,000 1,772,000 2,194,000 1,855,000 2,186,000 2,339,000 2,214,000 2,088,000 944,000 2,180,000 2,489,000 2,804,000 2,576,000 2,979,000 2,854,000 -7,297,000 4,933,000 5,105,000 5,081,000 5,726,000 8,003,000 15,044,000 14,308,000 15,180,000 12,232,000 10,693,000 684,000 8,370,000 
      net loss attributable to common stockholders of bridgebio
    		-164,043,000 -192,863,000 -182,743,000 -181,903,000 -167,422,000 -265,050,000 -162,040,000 -73,456,000 -35,216,000 -168,148,000 -176,999,000 -157,899,000 -140,156,000 -137,591,000 -137,339,000 -9,856,000 -196,397,000 -147,177,000 -155,935,000 -96,348,000 -163,079,000 -119,981,000 -115,859,000 -121,034,000 -91,850,000 -73,458,000 -59,980,000  
      net income per share
    		-0.84 -0.99 -0.95 -0.95 -0.88 -1.42 -0.86 -0.39 -0.2 -0.96 -1.08 -0.98 -0.92 -0.92 -0.93 -0.07 -1.35 -1.02 -1.06 -0.66 -1.18 -1.01 -0.98 -1.03 -0.78 -0.62 -0.51  
      weighted-average shares used for eps calculation
    		194,789,897 191,527,482 191,854,152 190,517,215 190,145,253 186,075,873 188,510,372 187,586,680 178,705,310 162,791,511 163,308,632 160,535,435 152,645,635 147,473,076 147,937,817 146,684,804 145,882,149 144,356,619 146,662,756 146,754,299 138,627,729 117,995,457 118,168,063 117,012,062 117,803,438 105,099,089 117,071,188  
      cost of license, services and royalty revenue
    		 986,250 2,535,000 805,000                         
      restructuring, impairment and related charges
    		 2,554,000 8,841,000 805,000 570,000 4,693,000 4,621,000 2,891,000 3,400,000 754,000 272,000 3,531,000 3,369,000 7,691,000 5,016,000 8,396,000 22,662,000            
      gain on deconsolidation of subsidiaries
    		      52,027,000                      
      loss on extinguishments of debt
    		                            
      total other income
    		 -55,193,000 -41,283,000 -47,380,000 -65,236,000 -40,209,000 27,496,000 99,995,000  7,088,000 -21,796,000 -14,604,000 -16,569,000 -11,338,000 -11,077,000 77,617,000 -27,652,000 13,332,000 -11,517,000 -8,059,000 -3,578,000 -7,536,000 -10,228,000 -11,647,000 -1,595,000 -5,513,000 -6,132,000 -5,016,000 
      income before income taxes
    		 -194,755,000 -186,482,000 -181,658,000                         
      provision for income taxes
    		 -120,000 -1,545,000                          
      gain on deconsolidation of a subsidiary
    		       126,294,000                     
      losses on extinguishments of debt
    		                            
      income tax expense
    		   2,100,000                         
      cost of license and services revenue
    		    605,000                        
      revenue
    		     5,882,000 2,732,000 2,168,000 211,120,000 1,745,000 4,091,000 1,641,000                 
      cost of revenue
    		     2,084,000 598,000 598,000 598,000 598,000 598,000 599,000                 
      net loss from equity method investment
    		       -7,925,000                     
      other expense, net:
    		                            
      gain from sale of priority review voucher
    		               107,946,000             
      revenue:
    		                            
      product sales
    		             95,000   1,459,000 2,047,000 759,000 987,000         
      total revenue
    		            1,826,000 1,870,000 338,000 73,746,000 1,694,000 12,886,000 2,344,000 54,024,000         
      cost of license revenue and products sold
    		            651,000 647,000 739,000 700,000 1,348,000            
      other expense
    		            -601,000                
      license revenue
    		                235,000 10,839,000 1,585,000 53,037,000 462,000 122,000 8,127,000   13,819,000 26,741,000  
      cost of products sold
    		                 1,172,000 1,454,000 109,000         
      operating expenses:
    		                            
      general and administrative
    		                    45,407,000 37,437,000 36,016,000 37,969,000 34,262,000 34,972,000 23,495,000 16,918,000 
      total operating expenses
    		                    167,966,000 127,611,000 128,066,000 124,567,000 102,487,000 92,457,000 81,273,000 69,249,000 
      cost of license revenue
    		                          2,500,000  
      share in net loss of an equity method investment
    		                            
      loss from ml bio asset acquisition
    		                          -416,000  
      loss from pellepharm
    		                         -4,036,000 -6,589,000 -4,956,000 
      leo call option income
    		                         -253,000 276,000 226,000 
      net loss and comprehensive loss
    		                           -74,265,000 
      net loss and comprehensive loss attributable to bridgebio
    		                           -65,895,000 
      cumulative returns on redeemable convertible preferred units
    		                            
      net loss attributable to redeemable founder units and redeemable common units
    		                           -65,895,000 
      net loss per unit attributable to redeemable founder unitholders and redeemable common unitholders, basic and diluted
    		                           -3,460 
      total weighted-average redeemable founder units and redeemable common units used in computing net loss per unit, basic and diluted
    		                           19,033,838,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 
                                  
        assets
      		                            
        current assets:
      		                            
        cash and cash equivalents
      		879,891,000 570,119,000 642,951,000 748,953,000 540,599,000 681,101,000 266,324,000 407,958,000 475,222,000 375,935,000 505,213,000 302,438,000 407,368,000 376,689,000 483,235,000 470,098,000 371,550,000 393,772,000 180,347,000 378,420,000 471,176,000 356,082,000 366,967,000 540,919,000 757,049,000 363,773,000 413,973,000 293,803,000 
        marketable securities
      		60,295,000 17,363,000 2,991,000 7,939,000    39,813,000 44,469,000   30,869,000 34,122,000 51,580,000 75,080,000 218,466,000 261,904,000            
        accounts receivable
      		205,226,000 139,444,000 116,518,000 76,868,000 115,265,000 4,722,000              1,213,000         
        inventories
      		32,980,000 26,753,000 24,527,000 18,277,000 3,954,000                        
        prepaid expenses and other current assets
      		62,914,000 44,070,000 52,395,000 60,240,000 35,355,000 34,743,000 38,367,000 28,396,000 28,108,000 24,305,000 22,583,000 20,546,000 25,145,000 21,922,000 25,661,000 32,754,000 34,021,000 32,446,000 31,927,000 26,670,000 25,534,000 35,731,000 26,703,000 20,996,000 19,782,000 22,629,000 22,102,000 12,906,000 
        total current assets
      		1,241,306,000 797,749,000 839,382,000 912,277,000 695,173,000 720,692,000 444,578,000 616,236,000 783,424,000 477,593,000 587,670,000 432,884,000 552,702,000 548,853,000 642,219,000 771,280,000 716,230,000 888,858,000 639,710,000 909,871,000 945,114,000 642,824,000 745,384,000 861,935,000 924,957,000 568,622,000 558,155,000 306,709,000 
        equity method investments
      		61,529,000 79,972,000                           
        property and equipment
      		4,941,000 5,366,000 5,830,000 6,107,000 6,698,000 7,011,000 8,701,000 9,840,000 11,414,000 11,816,000 12,413,000 13,047,000 13,566,000 14,569,000 15,603,000 16,873,000 17,182,000 30,066,000 27,741,000 26,272,000 22,816,000 20,325,000 16,182,000 15,573,000 15,755,000 5,625,000 2,984,000 1,865,000 
        operating lease right-of-use assets
      		17,226,000 8,149,000 6,553,000 6,186,000 7,166,000 5,767,000 6,439,000 7,267,000 8,052,000 8,027,000 9,332,000 9,814,000 10,532,000 10,678,000 11,738,000 12,850,000 13,936,000 15,907,000 17,108,000 15,964,000 12,997,000 16,508,000 9,644,000 10,465,000 8,855,000    
        intangible assets
      		27,359,000 28,077,000 28,795,000 29,513,000 27,802,000 23,926,000 24,525,000 25,123,000 25,721,000 26,319,000 26,917,000 27,515,000 28,113,000 28,712,000 29,310,000 29,908,000 30,476,000 44,934,000 46,204,000          
        other assets
      		18,620,000 16,712,000 25,522,000 18,105,000 16,608,000 18,195,000 20,291,000 18,903,000 20,722,000 22,625,000 18,676,000 20,401,000 20,767,000 20,224,000 29,870,000 31,322,000 35,325,000 33,027,000 33,054,000 49,797,000 30,179,000 23,931,000 16,483,000 17,254,000 17,022,000 26,288,000 2,598,000 9,471,000 
        total assets
      		1,370,981,000 936,025,000 998,250,000 1,080,190,000 881,638,000 919,338,000 664,977,000 794,375,000 849,333,000 546,380,000 655,008,000 503,661,000 625,680,000 623,036,000 728,740,000 862,233,000 813,149,000 1,012,792,000 781,524,000 1,081,486,000 1,093,308,000 703,588,000 787,693,000 905,227,000 989,799,000 631,679,000 640,530,000 325,540,000 
        liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit
      		                            
        current liabilities:
      		                            
        accounts payable
      		29,058,000 36,228,000 18,702,000 26,134,000 27,525,000 9,618,000 13,363,000 18,126,000 4,728,000 10,655,000 4,472,000 3,874,000 4,076,000 11,558,000 10,158,000 8,793,000 10,107,000 11,884,000 12,035,000 22,329,000 10,340,000 8,945,000 9,839,000 12,835,000 13,086,000 8,852,000 10,270,000 16,065,000 
        accrued compensation and benefits
      		39,338,000 76,703,000 56,155,000 37,187,000 33,447,000 58,329,000 43,541,000 29,056,000 32,395,000 57,370,000 33,735,000 28,690,000 18,869,000 31,256,000 24,842,000 32,609,000 15,458,000 37,041,000 21,560,000 21,865,000 20,741,000 29,682,000 18,755,000 13,590,000 5,647,000 13,317,000 7,580,000 4,736,000 
        accrued research and development liabilities
      		54,430,000 41,436,000 34,619,000 31,295,000 33,630,000 34,272,000 40,997,000 33,178,000 40,933,000 29,765,000 29,244,000 28,298,000 37,064,000 39,803,000 44,564,000 50,091,000 43,342,000 44,138,000 37,645,000 55,620,000 33,423,000 27,290,000 24,901,000 37,241,000 29,522,000 20,896,000 13,198,000 9,419,000 
        operating lease liabilities, current portion
      		4,439,000 6,192,000 5,294,000 4,782,000 5,209,000 4,506,000 4,600,000 4,623,000 4,544,000 4,128,000 4,137,000 3,776,000 3,674,000 3,675,000 4,044,000 4,310,000 4,363,000 4,938,000 4,999,000 4,540,000 3,807,000 3,795,000 3,617,000 3,627,000 2,510,000    
        deferred revenue, current portion
      		6,115,000 7,190,000 9,087,000 10,540,000 11,620,000 14,604,000 11,771,000 15,098,000 13,957,000 6,096,000 6,592,000 6,210,000 6,675,000 8,156,000 7,518,000 7,190,000             
        2027 notes
      		547,483,000 547,015,000 546,549,000 546,088,000 545,628,000 545,173,000 544,719,000 544,270,000 543,823,000 543,379,000 542,938,000 542,501,000 542,065,000 541,634,000 541,205,000 540,779,000 540,355,000 539,934,000 539,517,000 539,102,000 538,690,000 383,436,000 378,502,000 373,651,000 368,923,000    
        other current liabilities
      		135,509,000 120,222,000 92,743,000 65,916,000 40,674,000                        
        total current liabilities
      		816,372,000 287,971,000 216,600,000 175,854,000 152,105,000 154,400,000 139,216,000 134,364,000 141,477,000 143,844,000 106,065,000 110,120,000 96,596,000 121,428,000 119,194,000 141,160,000 103,463,000 135,069,000 95,823,000 131,909,000 94,729,000 95,648,000 75,707,000 92,640,000 64,914,000 60,385,000 39,858,000 38,705,000 
        2033 notes
      		619,631,000                            
        2031 notes
      		565,045,000 564,565,000 564,087,000 563,597,000 563,124,000                        
        2029 notes
      		741,402,000 740,890,000 740,380,000 739,874,000 739,372,000 738,872,000 738,376,000 737,882,000 737,392,000 736,905,000 736,422,000 735,940,000 735,463,000 734,988,000 734,516,000 734,047,000 733,581,000 733,119,000 732,659,000 732,202,000 731,747,000        
        deferred royalty obligations
      		871,185,000 855,030,000 836,126,000 813,959,000                         
        operating lease liabilities, net of current portion
      		14,216,000 3,811,000 3,427,000 4,025,000 4,915,000 4,696,000 5,833,000 7,059,000 8,297,000 8,981,000 9,812,000 10,916,000 11,904,000 12,274,000 13,000,000 14,276,000 15,494,000 17,428,000 18,683,000 18,022,000 13,862,000 14,677,000 8,236,000 9,117,000 8,678,000    
        deferred revenue, net of current portion
      		11,776,000 13,080,000 13,131,000 14,667,000 17,508,000 17,095,000 18,627,000 16,961,000 19,890,000                    
        other long-term liabilities
      		229,000 244,000 679,000 545,000 352,000 286,000 377,000 485,000 595,000 9,361,000 11,785,000 13,326,000 17,501,000 26,643,000 28,226,000 28,631,000 26,829,000 22,069,000 27,578,000          
        total liabilities
      		3,639,856,000 3,012,606,000 2,920,979,000 2,858,609,000 2,520,303,000 2,376,950,000 1,883,369,000 1,876,468,000 1,886,191,000 1,888,915,000 1,848,743,000 1,853,299,000 1,839,293,000 1,867,960,000 1,859,113,000 1,877,246,000 1,853,836,000 1,878,371,000 1,517,398,000 1,537,111,000 1,481,402,000 595,702,000 569,306,000 577,715,000 537,728,000 155,703,000 116,263,000 114,049,000 
        commitments and contingencies
      		                            
        redeemable convertible noncontrolling interests
      		-951,000 -570,000 23,000 -445,000 -227,000 142,000 645,000 -223,000 525,000 478,000 1,403,000 333,000 -204,000 -1,589,000 -2,388,000 -1,499,000 336,000 1,423,000 2,967,000 1,865,000 1,271,000 1,630,000 2,574,000 1,906,000 3,053,000 2,243,000 2,570,000 175,000 
        stockholders’ deficit:
      		                            
        undesignated preferred stock, 0.001 par value...
      		                            
        common stock, 0.001 par value...
      		204,000 202,000 200,000 198,000 197,000 196,000 195,000 194,000 193,000 181,000 180,000 168,000 167,000 157,000 156,000 154,000 154,000 154,000 153,000 153,000 152,000 125,000 125,000 125,000 124,000 124,000 117,000  
        treasury stock
      		-405,776,000 -323,276,000 -323,276,000 -323,276,000 -323,276,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -275,000,000 -130,308,000 -125,000,000 -75,000,000 -75,000,000 -75,000,000 -75,000,000    
        additional paid-in capital
      		2,112,454,000 2,057,646,000 2,018,335,000 1,980,805,000 1,938,369,000 1,903,155,000 1,876,091,000 1,851,058,000 1,820,994,000 1,481,032,000 1,459,596,000 1,128,100,000 1,106,635,000 938,703,000 917,333,000 892,960,000 867,596,000 841,530,000 821,220,000 799,679,000 767,117,000 1,021,344,000 1,006,944,000 992,691,000 986,746,000 848,107,000 826,062,000  
        accumulated other comprehensive income
      		-8,000 12,000 2,000 1,000  8,000 5,000 -4,000 2,000 31,000 34,000 63,000      -132,000 19,000 36,000 -57,000 192,000 461,000 858,000 726,000 254,000 152,000  
        accumulated deficit
      		-3,985,237,000 -3,821,194,000 -3,628,331,000 -3,445,588,000 -3,263,685,000 -3,096,263,000 -2,831,213,000 -2,669,173,000 -2,595,717,000 -2,560,501,000 -2,392,353,000 -2,215,354,000 -2,057,455,000 -1,918,149,000 -1,780,558,000 -1,643,219,000 -1,633,363,000 -1,436,966,000 -1,289,789,000 -1,133,854,000 -1,037,506,000 -888,755,000 -768,774,000 -652,915,000 -531,881,000 -440,031,000 -366,573,000 -326,068,000 
        total bridgebio stockholders’ deficit
      		-2,278,363,000 -2,086,610,000 -1,933,070,000 -1,787,860,000 -1,648,395,000 -1,467,904,000 -1,229,922,000 -1,092,925,000 -1,049,528,000 -1,354,257,000 -1,207,543,000 -1,362,023,000 -1,225,665,000 -1,254,617,000 -1,138,417,000 -1,025,532,000 -1,040,996,000            
        noncontrolling interests
      		10,439,000 10,599,000 10,318,000 9,886,000 9,957,000 10,150,000 10,885,000 11,055,000 12,145,000 11,244,000 12,405,000 12,052,000 12,256,000 11,282,000 10,432,000 12,018,000 -27,000 3,412,000 4,556,000 6,804,000 5,929,000 48,350,000 52,057,000 59,847,000 68,303,000 65,279,000 61,939,000 48,391,000 
        total stockholders’ deficit
      		-2,267,924,000 -2,076,011,000 -1,922,752,000 -1,777,974,000 -1,638,438,000 -1,457,754,000 -1,219,037,000 -1,081,870,000 -1,037,383,000 -1,343,013,000 -1,195,138,000 -1,349,971,000 -1,213,409,000 -1,243,335,000 -1,127,985,000 -1,013,514,000 -1,041,023,000            
        total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit
      		1,370,981,000 936,025,000 998,250,000 1,080,190,000 881,638,000 919,338,000 664,977,000 794,375,000 849,333,000 546,380,000 655,008,000 503,661,000 625,680,000 623,036,000 728,740,000 862,233,000 813,149,000            
        term loan
      		     437,337,000 436,221,000 435,447,000 434,717,000 446,445,000 441,721,000 440,496,000 435,764,000 430,993,000 422,972,000 418,353,000 434,114,000            
        investment in nonconsolidated entities
      		  92,168,000 108,002,000 128,191,000 143,747,000 160,443,000                      
        deferred royalty obligation
      		    497,299,000 479,091,000                       
        investments in equity securities
      		                            
        restricted cash
      		     126,000 139,409,000 139,409,000 131,000 16,653,000 16,652,000 19,930,000 25,503,000 37,930,000               
        accrued professional and other accrued liabilities
      		     33,071,000 24,944,000 34,283,000 44,920,000 35,830,000 27,885,000 39,272,000                 
        receivables from licensing and collaboration agreements
      		      478,000 660,000 235,494,000                    
        investment in nonconsolidated entity
      		       117,006,000                     
        investment in equity securities
      		         58,949,000 38,052,000 50,487,000 49,803,000 43,653,000 33,662,000 27,141,000 37,772,000 49,148,000 17,707,000 18,894,000         
        receivable from licensing and collaboration agreements
      		         1,751,000 5,170,000 8,614,000 10,761,000 17,079,000 24,581,000 22,821,000 10,983,000 19,749,000 7,710,000 35,363,000         
        accrued professional services
      		            4,015,000 1,790,000 4,230,000 6,183,000 5,411,000 6,786,000 4,976,000 6,378,000 4,518,000 5,579,000 4,706,000 8,609,000 3,145,000 2,222,000   
        other accrued liabilities
      		            22,223,000 25,190,000 23,838,000 31,984,000 24,782,000 30,282,000 14,608,000 21,177,000 18,254,000 13,349,000 8,691,000 11,462,000 7,465,000 3,020,000 4,789,000 4,188,000 
        accumulated other comprehensive loss
      		            -12,000 -328,000 -348,000 -427,000 -383,000            
        short-term marketable securities
      		                 393,743,000 419,264,000 459,243,000 447,942,000 251,011,000 343,714,000 300,020,000 148,126,000 182,220,000 122,080,000  
        liabilities, redeemable convertible noncontrolling interests and stockholders’ equity
      		                            
        leo call option liability
      		                     5,550,000 5,198,000 5,276,000 3,539,000 4,078,000 4,021,000 4,297,000 
        term loans, current portion
      		                    3,646,000 1,458,000       
        term loans, net of current portion
      		                 430,752,000 103,138,000 102,611,000 90,762,000 92,421,000       
        stockholders’ equity
      		                            
        total bridgebio stockholders’ equity
      		                 -870,414,000 -743,397,000 -464,294,000 -395,294,000 57,906,000       
        total stockholders’ equity
      		                 -867,002,000 -738,841,000 -457,490,000 -389,365,000 106,256,000       
        total liabilities, redeemable convertible noncontrolling interests and stockholders’ equity
      		                 1,012,792,000 781,524,000 1,081,486,000 1,093,308,000 703,588,000 787,693,000 905,227,000 989,799,000 631,679,000 640,530,000  
        receivable from a related party
      		                  462,000 8,962,000 462,000  8,000,000      
        long-term marketable securities
      		                   60,688,000 82,202,000    23,210,000 31,144,000 75,886,000  
        other liabilities
      		                   13,265,000 11,612,000 9,520,000 13,469,000 9,399,000 2,797,000 3,527,000 1,388,000 347,000 
        build-to-suit lease obligation
      		                         8,000,000   
        stockholders’ equity:
      		                            
        term loans, noncurrent
      		                      93,392,000 92,908,000 92,416,000 91,791,000 75,017,000 74,997,000 
        total bridgebio stockholders' equity
      		                      163,756,000 265,759,000 380,715,000 408,454,000 459,758,000  
        total stockholders' equity
      		                      215,813,000 325,606,000 449,018,000 473,733,000 521,697,000  
        investments in nonconsolidated entities
      		                            
        accrued distributions to stockholders
      		                            
        pellepharm investment
      		                          907,000 7,495,000 
        liabilities, redeemable convertible preferred units, redeemable founder units, redeemable common units, management incentive units, redeemable convertible noncontrolling interests, and members’ deficit
      		                            
        accrued distributions to unitholders
      		                            
        redeemable convertible preferred units
      		                           479,044,000 
        redeemable founder units
      		                           1,754,000 
        redeemable common units
      		                           1,672,000 
        management incentive units
      		                           6,523,000 
        members’ deficit:
      		                            
        total bridgebio members’ deficit
      		                           -326,068,000 
        total members’ deficit
      		                           -277,677,000 
        total liabilities, redeemable convertible preferred units, redeemable founder units, redeemable common units, management incentive units, redeemable convertible noncontrolling interests, and members’ deficit
      		                           325,540,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 
                                   
          operating activities:
        		                           
          net loss
        		-166,555,000 -194,635,000 -184,937,000 -183,758,000 -169,608,000 -267,389,000 -164,254,000     -160,703,000 -142,732,000 -140,570,000 -140,193,000 -2,559,000 -201,330,000 -152,282,000 -161,016,000 -102,074,000 -171,082,000 -135,025,000 -130,167,000 -136,214,000 -104,082,000 -84,151,000 -60,733,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                           
          stock-based compensation
        		33,242,000 34,639,000 35,262,000 37,241,000 25,882,000 30,127,000 27,162,000 21,454,000 17,057,000 37,025,000 22,600,000 27,178,000 21,907,000 21,789,000 17,361,000 28,287,000 24,122,000 19,774,000 16,042,000 30,112,000 33,577,000 12,146,000 17,699,000 18,392,000 10,222,000   
          net loss from equity method investments
        		18,283,000 21,029,000 15,834,000 20,189,000 15,556,000 16,695,000                      
          noncash interest expense on deferred royalty obligations
        		39,873,000 38,678,000                          
          change in fair value of the embedded derivative associated with the deferred royalty obligation
        		-2,158,000 -8,590,000                          
          amortization of debt discount and issuance costs
        		1,819,000 1,452,000                          
          depreciation and amortization
        		1,186,000 1,435,000 1,398,000 1,317,000 1,284,000 1,367,000 1,538,000 1,574,000 1,596,000 1,585,000 1,639,000 1,637,000 1,633,000 1,660,000 1,645,000 1,582,000 1,884,000 1,526,000 265,000        374,000 
          noncash lease expense
        		1,466,000 1,459,000 1,213,000 1,236,000 994,000 991,000 1,026,000 1,024,000 1,069,000 1,008,000 1,000,000 992,000 1,032,000    1,545,000 1,533,000          
          loss on extinguishment of debt
        		    21,155,000 0 0 0 26,590,000                   
          other noncash adjustments
        		306,000 -434,000 4,247,000 -1,491,000 -3,973,000 -697,000 -148,000 -3,542,000 1,631,000 565,000 -56,000 -125,000 -203,000 -4,083,000 945,000 3,138,000 604,000 -1,421,000 1,307,000 2,110,000 5,096,000 -4,643,000 4,844,000 1,446,000 1,034,000   
          changes in operating assets and liabilities:
        		                           
          accounts receivable
        		-65,782,000 -22,926,000 -39,650,000 38,397,000 -110,543,000                       
          inventories
        		-7,053,000 -1,951,000 -6,774,000 -13,389,000 -3,193,000                       
          prepaid expenses and other current assets
        		-18,845,000 8,750,000 5,218,000 -22,258,000 -487,000 3,625,000 -11,037,000 -3,161,000 -3,345,000 -1,722,000 -2,037,000 4,599,000 -3,542,000 3,599,000 7,093,000 -364,000 -2,657,000 -519,000 -5,143,000 -48,000 1,448,000 -1,668,000 -7,025,000 -1,212,000 2,846,000 -951,000 -9,196,000 
          other assets
        		-1,795,000 545,000 742,000 -1,761,000 1,587,000 1,970,000 -1,370,000 498,000 444,000 -2,989,000 1,411,000 515,000 -483,000 876,000 1,404,000 790,000 7,901,000 -886,000 -3,207,000 390,000 -6,113,000 -1,952,000 771,000 -231,000 -734,000 -15,265,000 413,000 
          accounts payable
        		-7,170,000 17,525,000 -7,432,000 -1,055,000 17,571,000 -3,745,000 -3,601,000 14,785,000 -5,927,000 6,184,000 694,000 -298,000 -3,800,000 1,376,000 1,365,000 -1,276,000 -1,814,000 1,473,000 -11,665,000 11,233,000 1,792,000 -1,282,000 -3,436,000 -251,000 4,234,000 -1,418,000 -3,385,000 
          accrued compensation and benefits
        		-37,476,000 19,810,000 18,849,000 3,726,000 -19,363,000 11,406,000 13,958,000 6,591,000 -14,969,000 11,958,000 6,915,000 7,298,000 -18,369,000 6,760,000 280,000 7,474,000 -16,876,000 11,821,000 4,051,000 4,487,000 -12,981,000 6,194,000 4,446,000 5,619,000 -7,670,000 5,737,000 2,844,000 
          accrued research and development liabilities
        		12,994,000 6,816,000 3,324,000 -2,335,000 -642,000 -6,725,000 8,387,000 -4,101,000 11,168,000 689,000 778,000 -8,766,000 -2,556,000 -4,761,000 -5,501,000 6,771,000 -818,000 6,492,000 2,223,000 -3,671,000 6,134,000 2,166,000 -12,341,000 7,719,000 8,626,000 7,697,000 3,779,000 
          operating lease liabilities
        		-1,852,000 -1,790,000 -1,640,000 -1,647,000 -1,470,000 -1,443,000 -1,478,000 -1,386,000 -1,595,000 -1,158,000 -1,228,000 -1,193,000 -1,250,000 -1,426,000 -1,471,000 -1,528,000 -1,820,000 -1,648,000 -1,698,000 -1,438,000 -1,338,000 -1,163,000 -891,000 -862,000 -556,000   
          deferred revenue
        		-2,379,000 -1,948,000 -2,989,000 -3,920,000 -2,571,000 1,300,000 -1,661,000 -1,788,000 24,024,000 -974,000 -1,280,000 -1,436,000 -1,748,000 -1,707,000 328,000             
          other liabilities
        		4,617,000 24,780,000                        0 83,000 
          net cash from operating activities
        		-197,279,000 -56,420,000 -109,574,000 -80,681,000 -199,235,000 -195,326,000 -180,566,000 74,703,000 -219,537,000 -124,819,000 -145,226,000 -113,353,000 -144,322,000 -93,243,000 -135,163,000 -30,453,000 -160,635,000 -133,895,000 -121,561,000 -91,713,000 -150,765,000 -96,261,000 -131,684,000 -87,849,000 -83,920,000 -76,203,000 -49,996,000 
          capital expenditures
        		-69,000 -33,000 -470,000 0  -47,000 -137,000 -54,000 -695,000 -435,000 -431,000 -428,000 -12,000 -801,000 -759,000 -2,402,000 -859,000 -2,536,000 -6,462,000 -2,287,000 -1,961,000 -2,146,000 -549,000 -346,000 -4,477,000 -1,747,000 -381,000 
          free cash flows
        		-197,348,000 -56,453,000 -110,044,000 -80,681,000  -195,373,000 -180,703,000 74,649,000 -220,232,000 -125,254,000 -145,657,000 -113,781,000 -144,334,000 -94,044,000 -135,922,000 -32,855,000 -161,494,000 -136,431,000 -128,023,000 -94,000,000 -152,726,000 -98,407,000 -132,233,000 -88,195,000 -88,397,000 -77,950,000 -50,377,000 
          investing activities:
        		                           
          purchases of marketable securities
        		-52,666,000 -17,321,000 -2,968,000   0 0 -49,416,000 -44,395,000 0 -9,972,000   -2,858,000 -15,024,000 -63,889,000 -55,722,000 -14,414,000 -65,544,000 -130,643,000 -379,291,000 -18,050,000 -101,001,000   -15,154,000  
          maturities of marketable securities
        		10,000,000 3,000,000    0 40,000,000   0 41,000,000 23,550,000 18,000,000 26,869,000 158,900,000 107,224,000 186,695,000 75,000,000 66,266,000 139,734,000 99,200,000 110,121,000 56,500,000 40,016,000 42,500,000   
          payment for an intangible asset
        		    -1,595,000 -3,190,000 -1,595,000 -2,393,000 -797,000      0             
          purchases of property and equipment
        		-69,000 -33,000 -470,000   -47,000 -137,000 -54,000 -695,000 -435,000 -431,000 -428,000 -12,000 -801,000 -759,000 -2,402,000 -859,000 -2,536,000 -6,462,000 -2,287,000 -1,961,000 -2,146,000 -549,000 -346,000 -4,477,000 -1,747,000 -381,000 
          net cash from investing activities
        		-42,735,000 -14,354,000 4,464,000 -13,002,000 -1,595,000 -3,237,000 38,226,000 3,039,000 22,753,000 -66,000 37,682,000 4,119,000 12,298,000 17,965,000 146,857,000 149,702,000 138,623,000 21,800,000 58,968,000 458,000 -282,052,000 83,018,000 -45,050,000 -128,984,000 38,023,000 -16,901,000 -197,342,000 
          financing activities:
        		                           
          proceeds from issuance of 2033 notes
        		632,500,000                           
          issuance costs and discounts associated with 2033 notes
        		-12,796,000                           
          proceeds from issuance of 2031 notes
        		 0 0 0 575,000,000                       
          issuance costs and discounts associated with 2031 notes
        		 0 0 0 -12,034,000                       
          repurchase of common stock
        		-82,500,000 0 0 0 -48,276,000               -5,308,000 -50,000,000 0 0 0 -75,000,000   
          repayment of term loans
        		 0 0 0 -459,000,000                       
          repayments of deferred royalty obligations
        		-11,293,000 -8,564,000                          
          proceeds from common stock issuances under espp
        		5,466,000 0 3,177,000                         
          proceeds from stock option exercises, net of repurchases
        		22,589,000 13,212,000 4,843,000 7,159,000 2,521,000 2,848,000 30,000 241,000 537,000 786,000 4,910,000 119,000 193,000 57,000 449,000 56,000 104,000 2,349,000 3,078,000 3,752,000 7,464,000 10,002,000 820,000 1,367,000 734,000   
          transactions with noncontrolling interests
        		 600,000 0 750,000 800,000     -2,301,000         3,430,000         
          repurchase of rsu shares to satisfy tax withholding
        		-4,074,000 -7,430,000 -3,025,000 -1,995,000 -1,776,000 -1,404,000 -1,443,000 -1,743,000 -2,936,000                   
          net cash from financing activities
        		549,892,000 -2,182,000 -894,000 302,041,000 60,328,000 473,931,000 707,000 -5,729,000 279,548,000 -4,523,000 307,040,000 -1,231,000 150,249,000 6,377,000 1,445,000 -20,796,000 -160,000 325,381,000 -135,456,000 -1,391,000 547,912,000 4,531,000 2,782,000 703,000 439,173,000 42,904,000 367,508,000 
          net increase in cash, cash equivalents, and restricted cash
        		309,878,000                           
          cash, cash equivalents, and restricted cash at beginning of period
        		572,140,000                           
          cash, cash equivalents, and restricted cash at end of period
        		882,018,000                           
          loss on extinguishments of debt
        		 0                          
          noncash income from equity method investments
        		                           
          loss on deconsolidation of subsidiaries
        		     0 -52,027,000                     
          gain from investment in equity securities
        		       0 -8,136,000                   
          accrual of payment-in-kind interest on term loan
        		         3,465,000 0 3,403,000 3,339,000               
          purchases of investments in equity securities
        		     0 0 0 -20,271,000                   
          proceeds from sales of investments in equity securities
        		     0 0 0 63,229,000                   
          proceeds from special cash dividends received from an investment in equity securities
        		 0                          
          payment for intangible assets
        		 0 -2,400,000                         
          decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries
        		     0 -42,000                     
          proceeds from a royalty obligation under the royalty purchase agreement
        		 0                          
          issuance costs associated with a royalty obligation under the royalty purchase agreement
        		 0                          
          proceeds from royalty obligation under funding agreement
        		                           
          issuance costs and discounts associated with royalty obligation under funding agreement
        		                           
          proceeds from term loan under the amended financing agreement
        		                           
          issuance costs and discounts associated with term loan under the amended financing agreement
        		                           
          proceeds from issuance of common stock through public offerings
        		     0 -18,000 -495,000 315,254,000                   
          cash, cash equivalents, and restricted cash at beginning of year
        		                           
          cash, cash equivalents, and restricted cash at end of year
        		                           
          noncash income from an equity method investment
        		                           
          gain on deconsolidation of subsidiaries
        		                           
          net increase in cash, cash equivalents and restricted cash
        		  -106,004,000 208,358,000 -140,502,000 275,368,000 -141,633,000 72,013,000 82,764,000 -129,408,000 199,496,000 -110,465,000 18,225,000 -68,901,000 13,139,000 98,453,000 -22,172,000 213,286,000 -198,049,000 -92,646,000 115,095,000 -8,712,000 -173,952,000 -216,130,000 393,276,000 -50,200,000 120,170,000 
          cash, cash equivalents and restricted cash at beginning of period
        		  0 0 683,244,000  0 0 394,732,000 0 0 0 416,884,000  0 0 396,365,000 0 0 0 358,679,000 0 0 0 364,197,000 0 0 
          cash, cash equivalents and restricted cash at end of period
        		  -106,004,000 208,358,000 542,742,000  -141,633,000 72,013,000 477,496,000 -129,408,000 199,496,000 -110,465,000 435,109,000  13,139,000 98,453,000 374,193,000 213,286,000 -198,049,000 -92,646,000 473,774,000 -8,712,000 -173,952,000 -216,130,000 757,473,000 -50,200,000 120,170,000 
          losses on extinguishments of debt
        		                           
          accretion of debt
        		   27,465,000 25,641,000 10,364,000 1,716,000 1,668,000 2,015,000 2,183,000 2,144,000 2,242,000 2,338,000 2,101,000 2,086,000 1,900,000 2,483,000 1,752,000 1,390,000 1,404,000 1,249,000       
          gain on deconsolidation of a subsidiary
        		                           
          dividend from investment in equity securities
        		                           
          other current liabilities
        		   23,664,000 2,945,000                       
          proceeds from royalty obligation under royalty purchase agreement
        		                           
          issuance costs associated with royalty obligation under royalty purchase agreement
        		                           
          proceeds from term loan under amended financing agreement
        		                           
          issuance costs and discounts associated with term loan under amended financing agreement
        		                           
          repayment of deferred royalty obligation
        		   -1,861,000 -144,000                       
          proceeds from special cash dividends received from investments in equity securities
        		     0 0 0 25,682,000                   
          proceeds from bridgebio common stock issuances under espp
        		    3,237,000 0 2,138,000 0 2,364,000 1,000 1,588,000 0 1,809,000  1,592,000 0 966,000 0 2,169,000 0 1,652,000       
          loss from investment in equity securities
        		     0      -1,435,000 -964,000               
          fair value of shares issued under a license agreement
        		              0             
          loss on sale of certain assets
        		             0 0 0 6,261,000           
          impairment of long-lived assets
        		             0 67,000 0 12,653,000           
          gain from sale of priority review voucher, excluding transaction costs
        		             0 0             
          gain from recognition of receivable from licensing and collaboration agreement
        		             0 0 0 -12,500,000           
          accrued professional and other liabilities
        		     10,801,000 -5,522,000 166,000 -1,256,000 6,572,000 -7,385,000                 
          proceeds from sale of priority review voucher
        		              0             
          proceeds from sale of certain assets
        		             0 0 0 10,000,000           
          other financing activities
        		           -1,180,000 5,743,000               
          cash, cash equivalents and restricted cash at beginning of year
        		                           
          cash, cash equivalents and restricted cash at end of year
        		                           
          receivables from licensing and collaboration agreements
        		      182,000 234,834,000 -233,743,000                   
          proceeds from term loan under financing agreement
        		      0 0 450,000,000                   
          issuance costs and discounts associated with term loan under financing agreement
        		      0 -3,732,000 -12,254,000                   
          repayment of term loan under loan and security agreement
        		      0 0 -473,417,000                   
          net loss from equity method investment
        		                           
          fair value adjustment of warrants
        		         -1,036,000 274,000 -111,000 -111,000 125,000 56,000 538,000 852,000           
          net income
        		        -36,160,000                   
          adjustments to reconcile net income to net cash from operating activities:
        		                           
          loss on deconsolidation of pellepharm
        		         0 0 0 1,241,000               
          decrease in cash and cash equivalents resulting from deconsolidation of pellepharm
        		         0 0 0 -503,000               
          leo call option income
        		                    -5,550,000       
          loss on early extinguishment of debt
        		                           
          receivable from licensing and collaboration agreements
        		         3,419,000 3,443,000 2,148,000 6,318,000 16,001,000 -3,825,000 -7,273,000 10,266,000 -12,039,000 27,653,000         
          sales of marketable securities
        		                 -36,234,000          
          purchases of investment in equity securities
        		         -29,224,000 -6,810,000 -24,030,000 -47,474,000 -29,250,000 -15,382,000 -2,768,000 -8,162,000 -29,423,000          
          sales of investment in equity securities
        		         29,593,000 13,895,000 24,781,000 42,287,000 24,005,000 19,122,000 3,037,000 6,671,000 29,407,000          
          increase in cash and cash equivalents from consolidation of pellepharm
        		                 0 0         
          proceeds from issuance of common stock through private placement offering
        		         -454,000                  
          proceeds from issuance of common stock through follow-on offering
        		         0 0 1,033,000 143,016,000               
          proceeds from issuance of common stock through atm offering
        		         0                  
          proceeds from issuance of 2029 notes
        		                           
          issuance costs and discounts associated with issuance of 2029 notes
        		                           
          purchase of capped calls
        		                 0 0 0 -61,295,000 0 0 0 -49,280,000   
          repurchases of common stock
        		                           
          repurchase of eidos noncontrolling interest, including direct transaction costs
        		                 0 -250,000 -4,516,000 -80,324,000       
          proceeds from term loan, net of issuance costs
        		                           
          repayment of term loan
        		             0 0    0         
          income from investment in equity securities
        		                           
          repurchase of shares to satisfy tax withholding
        		          -2,610,000 -1,203,000 -512,000  -596,000 -366,000 -110,000 -711,000 -733,000 -2,281,000 -1,021,000 -471,000      
          issuance costs associated with term loan
        		              0 0 -1,120,000           
          accrued professional services
        		            2,225,000 -2,440,000 -1,954,000 772,000 -1,374,000 1,811,000 -1,153,000 1,859,000 -360,000 1,256,000 -5,237,000 5,465,000 923,000   
          other accrued and other long-term liabilities
        		            -8,597,000 -6,530,000 -4,590,000 11,270,000 -2,883,000 13,636,000          
          operating activities
        		                           
          net loss from investment in equity securities
        		             -4,747,000 -10,259,000 10,362,000 12,866,000           
          fair value of shares issued under license agreements
        		                           
          leo call option expense
        		                 0 0   352,000 -78,000 1,737,000 -539,000 57,000 -276,000 
          acquired in-process research and development assets
        		                         0 1,060,000 
          receivable from a related party
        		                  8,500,000 -8,500,000 -462,000 8,000,000      
          investing activities
        		                           
          proceeds from sale of priority review voucher, excluding transaction costs
        		                           
          other investing activities
        		                           
          financing activities
        		                           
          proceeds from issuance of 2029 notes in 2021 and 2027 notes in 2020
        		                 0 0 0 747,500,000       
          issuance costs and discounts associated with issuance of 2029 notes and 2027 notes
        		                 0 0 0 -16,064,000       
          proceeds from issuance of noncontrolling interests
        		                           
          repurchase of common stock to satisfy tax withholding
        		                           
          proceeds from at-the-market issuance of noncontrolling interest by eidos
        		                     0 0 0 24,094,000   
          proceeds from issuance of common stock through at-the-market offering
        		                           
          repurchase of noncontrolling interest
        		                         0 -26,383,000 
          proceeds from term loan
        		                  0         
          net gains from investment in equity securities
        		                           
          share in net loss of equity method investments
        		                           
          acquisition of intangible assets
        		                 0          
          others
        		                           
          proceeds from issuance of common stock in connection with initial public offering
        		                           
          proceeds from issuance of noncontrolling interest to alexion
        		                         0  
          proceeds from term loans, net of issuance costs
        		                         17,152,000 0 
          proceeds from disposal of property and equipment
        		                     0 0     
          supplemental disclosures of cash flow information:
        		                           
          cash paid for interest
        		                  17,425,000 1,901,000 8,913,000 2,041,000 9,159,000 2,068,000 2,054,000 1,756,000 1,753,000 
          supplemental disclosures of noncash investing and financing information:
        		                           
          net noncash portion of repurchase of eidos noncontrolling interests
        		                  0 0 38,167,000       
          direct transaction costs in the repurchase of eidos recorded in additional paid-in capital previously classified in prepaid expenses and other current assets
        		                  0 0 8,749,000       
          noncash contribution by a noncontrolling interest
        		                           
          deferred merger transaction costs included in accounts payable and accrued professional services
        		                     315,000      
          recognized intangible asset recorded in other accrued liabilities and other long-term liabilities
        		                           
          leasehold improvements paid by landlord
        		                           
          repurchase of common stock recorded in accounts payable
        		                           
          recognition of property and equipment previously classified in other assets
        		                     0 0 0 10,000,000   
          transfers from
        		                      1,080,000 -3,109,000 11,601,000   
          other accrued and other liabilities
        		                   6,139,000 -3,540,000 3,445,000 -449,000 5,324,000 15,000   
          investment in equity securities
        		                           
          noncash contribution by an nci
        		                           
          recognized intangible asset recorded in accrued research and development liabilities
        		                           
          leasehold improvement paid by landlord
        		                           
          transfers from noncontrolling interests
        		                   -1,416,000 1,690,000       
          amortization of operating lease right-of-use assets
        		                    1,365,000       
          proceeds from issuance of redeemable convertible noncontrolling interests to third-party investors
        		                     0 1,000,000 0 1,000,000   
          supplemental disclosures of non-cash investing and financing information:
        		                           
          direct transaction costs in the repurchase of eidos noncontrolling interest included in accounts payable and accrued professional services
        		                    4,766,000       
          issuance costs associated with issuance of 2027 notes included in other accrued and other liabilities
        		                        664,000   
          unpaid property and equipment
        		                    1,787,000       
          gain on deconsolidation of pellepharm
        		                           
          change in fair value of lianbio warrants
        		                           
          fair value of equity method investment
        		                           
          accretion of 2027 notes and term loans
        		                     5,422,000 5,335,000 5,219,000 1,761,000   
          change in fair value of eidos financial instruments
        		                           
          payments of merger transaction costs
        		                           
          cash paid for in-process research and development assets acquired
        		                         0 0 
          cash and cash equivalents acquired in ml bio asset acquisition
        		                         0  
          proceeds from issuance of common stock in connection with the initial public offering of bridgebio in 2019 and eidos in 2018, net of underwriting discounts and commissions
        		                           
          proceeds from issuance of 2027 notes
        		                     0 0 0 550,000,000   
          issuance costs and discounts associated with issuance of 2027 notes
        		                     0 0 -664,000 -12,375,000   
          proceeds from issuance of promissory notes
        		                           
          proceeds from repayment of nonrecourse notes
        		                         0 0 
          proceeds from the issuance of redeemable convertible preferred units, net of issuance costs
        		                           
          proceeds from repayment of the loans received by noncontrolling interest shareholder
        		                           
          myokardia distributions
        		                         0 0 
          tenant improvement paid by landlord
        		                         1,138,000  
          transfers
        		                           
          non-cash contribution by a noncontrolling interest
        		                           
          build-to-suit funding liability accrual
        		                           
          fair value of success fee derivative at issuance of eidos term loan
        		                           
          conversion of redeemable noncontrolling interest into noncontrolling interest
        		                           
          conversion of promissory note into redeemable convertible noncontrolling interest
        		                           
          fair value of redeemable convertible noncontrolling interest issued for acquired in-process research and development assets
        		                           
          proceeds from issuance of common stock in connection with the initial public offering
        		                           
          operating lease right-of-use assets obtained in exchange for operating lease obligations
        		                      0 2,419,000 9,395,000   
          payment of deferred offering costs
        		                           
          deferred offering costs included in accounts payable and other accrued liabilities
        		                           
          accretion of term loans and convertible promissory notes
        		                         787,000 20,000 
          other accrued liabilities
        		                         -1,162,000 2,184,000 
          proceeds from issuance of common stock in connection with the initial public offering of the corporation in 2019 and eidos in 2018, net of underwriting discounts and commissions
        		                           
          proceeds from third-party investors in redeemable convertible noncontrolling interests
        		                         0  
          proceeds from stock option exercises
        		                           
          conversion of promissory note upon issuance of series c redeemable convertible preferred units
        		                           
          capital transaction upon merger
        		                           
          net accretion and amortization of premium and discounts on marketable securities
        		                           
          equity-based compensation
        		                          5,846,000 
          loss on disposal of property and equipment
        		                          55,000 
          loss from ml bio asset acquisition
        		                           
          loss from pellepharm
        		                          6,589,000 
          shares issued under license agreements
        		                          0 
          proceeds from issuance of bridgebio pharma llc common stock equivalents, net of issuance costs
        		                           
          proceeds from issuance of common stock in connection with the initial public offering, net of underwriting discounts and commissions
        		                           
          proceeds from issuance of common stock in connection with the initial public offering of eidos, net of underwriting discounts and commissions
        		                           
          issuance of loan to noncontrolling interest shareholder
        		                           
          proceeds from subsidiary stock option exercises
        		                          346,000 
          transfers to
        		                          13,529,000 
          proceeds from the issuance of series c preferred units, net of issuance costs